Abstract / Description of output
Background: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. Funding: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.
Original language | English |
---|---|
Pages (from-to) | 99-111 |
Number of pages | 13 |
Journal | The Lancet |
Volume | 397 |
Issue number | 10269 |
Early online date | 8 Dec 2020 |
DOIs | |
Publication status | Published - 9 Jan 2021 |
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet, Vol. 397, No. 10269, 09.01.2021, p. 99-111.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2
T2 - an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
AU - Oxford COVID Vaccine Trial Group
AU - Voysey, Merryn
AU - Clemens, Sue Ann Costa
AU - Madhi, Shabir A.
AU - Weckx, Lily Y.
AU - Folegatti, Pedro M.
AU - Aley, Parvinder K.
AU - Angus, Brian
AU - Baillie, Vicky L.
AU - Barnabas, Shaun L.
AU - Bhorat, Qasim E.
AU - Bibi, Sagida
AU - Briner, Carmen
AU - Cicconi, Paola
AU - Collins, Andrea M.
AU - Colin-Jones, Rachel
AU - Cutland, Clare L.
AU - Darton, Thomas C.
AU - Dheda, Keertan
AU - Duncan, Christopher J.A.
AU - Emary, Katherine R.W.
AU - Ewer, Katie J.
AU - Fairlie, Lee
AU - Faust, Saul N.
AU - Feng, Shuo
AU - Ferreira, Daniela M.
AU - Finn, Adam
AU - Goodman, Anna L.
AU - Green, Catherine M.
AU - Green, Christopher A.
AU - Heath, Paul T.
AU - Hill, Catherine
AU - Hill, Helen
AU - Hirsch, Ian
AU - Hodgson, Susanne H.C.
AU - Izu, Alane
AU - Jackson, Susan
AU - Jenkin, Daniel
AU - Joe, Carina C.D.
AU - Kerridge, Simon
AU - Koen, Anthonet
AU - Kwatra, Gaurav
AU - Lazarus, Rajeka
AU - Lawrie, Alison M.
AU - Lelliott, Alice
AU - Libri, Vincenzo
AU - Lillie, Patrick J.
AU - Mallory, Raburn
AU - Mendes, Ana V.A.
AU - Milan, Eveline P.
AU - Minassian, Angela M.
AU - McGregor, Alastair
AU - Morrison, Hazel
AU - Mujadidi, Yama F.
AU - Nana, Anusha
AU - O'Reilly, Peter J.
AU - Padayachee, Sherman D.
AU - Pittella, Ana
AU - Plested, Emma
AU - Pollock, Katrina M.
AU - Ramasamy, Maheshi N.
AU - Rhead, Sarah
AU - Schwarzbold, Alexandre V.
AU - Singh, Nisha
AU - Smith, Andrew
AU - Song, Rinn
AU - Snape, Matthew D.
AU - Sprinz, Eduardo
AU - Sutherland, Rebecca K.
AU - Tarrant, Richard
AU - Thomson, Emma C.
AU - Török, M. Estée
AU - Toshner, Mark
AU - Turner, David P.J.
AU - Vekemans, Johan
AU - Villafana, Tonya L.
AU - Watson, Marion E.E.
AU - Williams, Christopher J.
AU - Douglas, Alexander D.
AU - Hill, Adrian V.S.
AU - Lambe, Teresa
AU - Gilbert, Sarah C.
AU - Pollard, Andrew J.
AU - Aban, Marites
AU - Abayomi, Fatola
AU - Abeyskera, Kushala
AU - Aboagye, Jeremy
AU - Adam, Matthew
AU - Adams, Kirsty
AU - Adamson, James
AU - Adelaja, Yemi A.
AU - Adewetan, Gbadebo
AU - Adlou, Syed
AU - Ahmed, Khatija
AU - Akhalwaya, Yasmeen
AU - Akhalwaya, Saajida
AU - Alcock, Andrew
AU - Ali, Aabidah
AU - Allen, Elizabeth R.
AU - Allen, Lauren
AU - Almeida, Thamires C.D.S.C.
AU - Alves, Mariana P.S.
AU - Amorim, Fabio
AU - Andritsou, Foteini
AU - Anslow, Rachel
AU - Appleby, Matthew
AU - Arbe-Barnes, Edward H.
AU - Ariaans, Mark P.
AU - Arns, Beatriz
AU - Arruda, Laiana
AU - Azi, Paula
AU - Azi, Lorena
AU - Babbage, Gavin
AU - Bailey, Catherine
AU - Baker, Kenneth F.
AU - Baker, Megan
AU - Baker, Natalie
AU - Baker, Philip
AU - Baldwin, Lisa
AU - Baleanu, Ioana
AU - Bandeira, Danieli
AU - Bara, Anna
AU - Barbosa, Marcella A.S.
AU - Barker, Debbie
AU - Barlow, Gavin D.
AU - Barnes, Eleanor
AU - Barr, Andrew S.
AU - Barrett, Jordan R.
AU - Barrett, Jessica
AU - Bates, Louise
AU - Batten, Alexander
AU - Beadon, Kirsten
AU - Beales, Emily
AU - Beckley, Rebecca
AU - Belij-Rammerstorfer, Sandra
AU - Bell, Jonathan
AU - Bellamy, Duncan
AU - Bellei, Nancy
AU - Belton, Sue
AU - Berg, Adam
AU - Bermejo, Laura
AU - Berrie, Eleanor
AU - Berry, Lisa
AU - Berzenyi, Daniella
AU - Beveridge, Amy
AU - Bewley, Kevin R.
AU - Bexhell, Helen
AU - Bhikha, Sutika
AU - Bhorat, Asad E.
AU - Bhorat, Zaheda E.
AU - Bijker, Else
AU - Birch, Geeta
AU - Birch, Sarah
AU - Bird, Adam
AU - Bird, Olivia
AU - Bisnauthsing, Karen
AU - Bittaye, Mustapha
AU - Blackstone, Katherine
AU - Blackwell, Luke
AU - Bletchly, Heather
AU - Blundell, Caitlin L.
AU - Blundell, Susannah R.
AU - Bodalia, Pritesh
AU - Boettger, Bruno C.
AU - Bolam, Emma
AU - Boland, Elena
AU - Bormans, Daan
AU - Borthwick, Nicola
AU - Bowring, Francesca
AU - Boyd, Amy
AU - Bradley, Penny
AU - Brenner, Tanja
AU - Brown, Phillip
AU - Brown, Claire
AU - Brown-O'Sullivan, Charlie
AU - Bruce, Scott
AU - Brunt, Emily
AU - Buchan, Ruaridh
AU - Budd, William
AU - Bulbulia, Yusuf A.
AU - Bull, Melanie
AU - Burbage, Jamie
AU - Burhan, Hassan
AU - Burn, Aileen
AU - Buttigieg, Karen R.
AU - Byard, Nicholas
AU - Cabera Puig, Ingrid
AU - Calderon, Gloria
AU - Calvert, Anna
AU - Camara, Susana
AU - Cao, Michelangelo
AU - Cappuccini, Federica
AU - Cardoso, João R.
AU - Carr, Melanie
AU - Carroll, Miles W.
AU - Carson-Stevens, Andrew
AU - Carvalho, Yasmin de M.
AU - Carvalho, José A.M.
AU - Casey, Helen R.
AU - Cashen, Paul
AU - Castro, Thais
AU - Castro, Lucia Carratala
AU - Cathie, Katrina
AU - Cavey, Ana
AU - Cerbino-Neto, José
AU - Chadwick, Jim
AU - Chapman, David
AU - Charlton, Sue
AU - Chelysheva, Irina
AU - Chester, Oliver
AU - Chita, Sunder
AU - Cho, Jee Sun
AU - Cifuentes, Liliana
AU - Clark, Elizabeth
AU - Clark, Matthew
AU - Clarke, Andrea
AU - Clutterbuck, Elizabeth A.
AU - Collins, Sarah L.K.
AU - Conlon, Christopher P.
AU - Connarty, Sean
AU - Coombes, Naomi
AU - Cooper, Cushla
AU - Cooper, Rachel
AU - Cornelissen, Lynne
AU - Corrah, Tumena
AU - Cosgrove, Catherine
AU - Cox, Tony
AU - Crocker, Wendy E.M.
AU - Crosbie, Sarah
AU - Cullen, Lorraine
AU - Cullen, Dan
AU - Cunha, Debora R.M.F.
AU - Cunningham, Christina
AU - Cuthbertson, Fiona C.
AU - Da Guarda, Suzete N.Farias
AU - da Silva, Larissa P.
AU - Damratoski, Brad E.
AU - Danos, Zsofia
AU - Dantas, Maria T.D.C.
AU - Darroch, Paula
AU - Datoo, Mehreen S.
AU - Datta, Chandrabali
AU - Davids, Malika
AU - Davies, Sarah L.
AU - Davies, Hannah
AU - Davis, Elizabeth
AU - Davis, Judith
AU - Davis, John
AU - De Nobrega, Maristela M.D.
AU - De Oliveira Kalid, Lis Moreno
AU - Dearlove, David
AU - Demissie, Tesfaye
AU - Desai, Amisha
AU - Di Marco, Stefania
AU - Di Maso, Claudio
AU - Dinelli, Maria I.S.
AU - Dinesh, Tanya
AU - Docksey, Claire
AU - Dold, Christina
AU - Dong, Tao
AU - Donnellan, Francesca R.
AU - Dos Santos, Tannyth
AU - dos Santos, Thainá G.
AU - Dos Santos, Erika Pachecho
AU - Douglas, Naomi
AU - Downing, Charlotte
AU - Drake, Jonathan
AU - Drake-Brockman, Rachael
AU - Driver, Kimberley
AU - Drury, Ruth
AU - Dunachie, Susanna J.
AU - Durham, Benjamin S.
AU - Dutra, Lidiana
AU - Easom, Nicholas J.W.
AU - van Eck, Samual
AU - Edwards, Mandy
AU - Edwards, Nick J.
AU - El Muhanna, Omar M.
AU - Elias, Sean C.
AU - Elmore, Mike
AU - English, Marcus
AU - Esmail, Alisgair
AU - Essack, Yakub Moosa
AU - Farmer, Eoghan
AU - Farooq, Mutjaba
AU - Farrar, Madi
AU - Farrugia, Leonard
AU - Faulkner, Beverley
AU - Fedosyuk, Sofiya
AU - Felle, Sally
AU - Ferreira Da Silva, Carla
AU - Field, Samantha
AU - Fisher, Richard
AU - Flaxman, Amy
AU - Fletcher, James
AU - Fofie, Hazel
AU - Fok, Henry
AU - Ford, Karen J.
AU - Fowler, Jamie
AU - Fraiman, Pedro H.A.
AU - Francis, Emma
AU - Franco, Marilia M.
AU - Frater, John
AU - Freire, Marilúcia S.M.
AU - Fry, Samantha H.
AU - Fudge, Sabrina
AU - Furze, Julie
AU - Fuskova, Michelle
AU - Galian-Rubio, Pablo
AU - Galiza, Eva
AU - Garlant, Harriet
AU - Gavrila, Madita
AU - Geddes, Ailsa
AU - Gibbons, Karyna A.
AU - Gilbride, Ciaran
AU - Gill, Hardeep
AU - Glynn, Sharon
AU - Godwin, Kerry
AU - Gokani, Karishma
AU - Goldoni, Ursula Carvalho
AU - Goncalves, Maria
AU - Gonzalez, Isabela G.S.
AU - Goodwin, Jayne
AU - Goondiwala, Amina
AU - Gordon-Quayle, Katherine
AU - Gorini, Giacomo
AU - Grab, Janet
AU - Gracie, Lara
AU - Greenland, Melanie
AU - Greenwood, Nicola
AU - Greffrath, Johann
AU - Groenewald, Marisa M.
AU - Grossi, Leonardo
AU - Gupta, Gaurav
AU - Hackett, Mark
AU - Hallis, Bassam
AU - Hamaluba, Mainga
AU - Hamilton, Elizabeth
AU - Hamlyn, Joseph
AU - Hammersley, Daniel
AU - Hanrath, Aidan T.
AU - Hanumunthadu, Brama
AU - Harris, Stephanie A.
AU - Harris, Clair
AU - Harris, Tara
AU - Harrison, Thomas D.
AU - Harrison, Daisy
AU - Hart, Thomas C.
AU - Hartnell, Birgit
AU - Hassan, Shadin
AU - Haughney, John
AU - Hawkins, Sophia
AU - Hay, Jodie
AU - Head, Ian
AU - Henry, John
AU - Hermosin Herrera, Macarena
AU - Hettle, David B.
AU - Hill, Jennifer
AU - Hodges, Gina
AU - Horne, Elizea
AU - Hou, Mimi M.
AU - Houlihan, Catherine
AU - Howe, Elizabeth
AU - Howell, Nicola
AU - Humphreys, Jonathan
AU - Humphries, Holly E.
AU - Hurley, Katrina
AU - Huson, Claire
AU - Hyder-Wright, Angela
AU - Hyams, Catherine
AU - Ikram, Sabina
AU - Ishwarbhai, Alka
AU - Ivan, Monica
AU - Iveson, Poppy
AU - Iyer, Vidyashankara
AU - Jackson, Frederic
AU - De Jager, Jeanne
AU - Jaumdally, Shameem
AU - Jeffers, Helen
AU - Jesudason, Natasha
AU - Jones, Bryony
AU - Jones, Kathryn
AU - Jones, Elizabeth
AU - Jones, Christopher
AU - Jorge, Marianna Rocha
AU - Jose, Aylin
AU - Joshi, Amar
AU - Júnior, Eduardo A.M.S.
AU - Kadziola, Joanne
AU - Kailath, Reshma
AU - Kana, Faeeza
AU - Karampatsas, Konstantinos
AU - Kasanyinga, Mwila
AU - Keen, Jade
AU - Kelly, Elizabeth J.
AU - Kelly, Dearbhla M.
AU - Kelly, Debbie
AU - Kelly, Sarah
AU - Kerr, David
AU - Kfouri, Renato de Ávila
AU - Khan, Liaquat
AU - Khozoee, Baktash
AU - Kidd, Sarah
AU - Killen, Annabel
AU - Kinch, Jasmin
AU - Kinch, Patrick
AU - King, Lloyd D.W.
AU - King, Thomas B.
AU - Kingham, Lucy
AU - Klenerman, Paul
AU - Knapper, Francesca
AU - Knight, Julian C.
AU - Knott, Daniel
AU - Koleva, Stanislava
AU - Lang, Matilda
AU - Lang, Gail
AU - Larkworthy, Colin W.
AU - Larwood, Jessica P.J.
AU - Law, Rebecca
AU - Lazarus, Erica M.
AU - Leach, Amanda
AU - Lees, Emily A.
AU - Lemm, Nana Marie
AU - Lessa, Alvaro
AU - Leung, Stephanie
AU - Li, Yuanyuan
AU - Lias, Amelia M.
AU - Liatsikos, Kostas
AU - Linder, Aline
AU - Lipworth, Samuel
AU - Liu, Shuchang
AU - Liu, Xinxue
AU - Lloyd, Adam
AU - Lloyd, Stephanie
AU - Loew, Lisa
AU - Lopez Ramon, Raquel
AU - Lora, Leandro
AU - Lowthorpe, Vicki
AU - Luz, Kleber
AU - MacDonald, Jonathan C.
AU - MacGregor, Gordon
AU - Madhavan, Meera
AU - Mainwaring, David O.
AU - Makambwa, Edson
AU - Makinson, Rebecca
AU - Malahleha, Mookho
AU - Malamatsho, Ross
AU - Mallett, Garry
AU - Mansatta, Kushal
AU - Maoko, Takalani
AU - Mapetla, Katlego
AU - Marchevsky, Natalie G.
AU - Marinou, Spyridoula
AU - Marlow, Emma
AU - Marques, Gabriela N.
AU - Marriott, Paula
AU - Marshall, Richard P.
AU - Marshall, Julia L.
AU - Martins, Flávia J.
AU - Masenya, Masebole
AU - Masilela, Mduduzi
AU - Masters, Shauna K.
AU - Mathew, Moncy
AU - Matlebjane, Hosea
AU - Matshidiso, Kedidimetse
AU - Mazur, Olga
AU - Mazzella, Andrea
AU - McCaughan, Hugh
AU - McEwan, Joanne
AU - McGlashan, Joanna
AU - McInroy, Lorna
AU - McIntyre, Zoe
AU - McLenaghan, Daniela
AU - McRobert, Nicky
AU - McSwiggan, Steve
AU - Megson, Clare
AU - Mehdipour, Savviz
AU - Meijs, Wilma
AU - Mendonça, Renata N.Á.
AU - Mentzer, Alexander J.
AU - Mirtorabi, Neginsadat
AU - Mitton, Celia
AU - Mnyakeni, Sibusiso
AU - Moghaddas, Fiona
AU - Molapo, Kgaogelo
AU - Moloi, Mapule
AU - Moore, Maria
AU - Moraes-Pinto, M. Isabel
AU - Moran, Marni
AU - Morey, Ella
AU - Morgans, Róisín
AU - Morris, Susan
AU - Morris, Sheila
AU - Morris, Helen C.
AU - Morselli, Franca
AU - Morshead, Gertraud
AU - Morter, Richard
AU - Mottal, Lynelle
AU - Moultrie, Andrew
AU - Moya, Nathifa
AU - Mpelembue, Mushiya
AU - Msomi, Sibekezelo
AU - Mugodi, Yvonne
AU - Mukhopadhyay, Ekta
AU - Muller, Jilly
AU - Munro, Alasdair
AU - Munro, Claire
AU - Murphy, Sarah
AU - Mweu, Philomena
AU - Myasaki, Celia Hatsuko
AU - Naik, Gurudutt
AU - Naker, Kush
AU - Nastouli, Eleni
AU - Nazir, Abida
AU - Ndlovu, Bongani
AU - Neffa, Fabio
AU - Njenga, Cecilia
AU - Noal, Helena
AU - Noé, Andrés
AU - Novaes, Gabrielle
AU - Nugent, Fay L.
AU - Nunes, Géssika
AU - O'Brien, Katie
AU - O'Connor, Daniel
AU - Odam, Miranda
AU - Oelofse, Suzette
AU - Oguti, Blanche
AU - Olchawski, Victoria
AU - Oldfield, Neil J.
AU - Oliveira, Marianne G.
AU - Oliveira, Catarina
AU - Oosthuizen, Angela
AU - O'Reilly, Paula
AU - Osborne, Piper
AU - Owen, David R.J.
AU - Owen, Lydia
AU - Owens, Daniel
AU - Owino, Nelly
AU - Pacurar, Mihaela
AU - Paiva, Brenda V.B.
AU - Palhares, Edna M.F.
AU - Palmer, Susan
AU - Parkinson, Sivapriyai
AU - Parracho, Helena M.R.T.
AU - Parsons, Karen
AU - Patel, Dipak
AU - Patel, Bhumika
AU - Patel, Faeezah
AU - Patel, Kelly
AU - Patrick-Smith, Maia
AU - Payne, Ruth O.
AU - Peng, Yanchun
AU - Penn, Elizabeth J.
AU - Pennington, Anna
AU - Peralta Alvarez, Marco Polo
AU - Perring, James
AU - Perry, Nicola
AU - Perumal, Rubeshan
AU - Petkar, Sahir
AU - Philip, Tricia
AU - Phillips, Daniel J.
AU - Phillips, Jennifer
AU - Phohu, Mary Kgomotso
AU - Pickup, Lorinda
AU - Pieterse, Sonja
AU - Piper, Jo
AU - Pipini, Dimitra
AU - Plank, Mary
AU - Du Plessis, Joan
AU - Pollard, Samuel
AU - Pooley, Jennifer
AU - Pooran, Anil
AU - Poulton, Ian
AU - Powers, Claire
AU - Presa, Fernando B.
AU - Price, David A.
AU - Price, Vivien
AU - Primeira, Marcelo
AU - Proud, Pamela C.
AU - Provstgaard-Morys, Samuel
AU - Pueschel, Sophie
AU - Pulido, David
AU - Quaid, Sheena
AU - Rabara, Ria
AU - Radford, Alexandra
AU - Radia, Kajal
AU - Rajapaska, Durga
AU - Rajeswaran, Thurkka
AU - Ramos, Alberto San Francisco
AU - Ramos Lopez, Fernando
AU - Rampling, Tommy
AU - Rand, Jade
AU - Ratcliffe, Helen
AU - Rawlinson, Tom
AU - Rea, David
AU - Rees, Byron
AU - Reiné, Jesús
AU - Resuello-Dauti, Mila
AU - Reyes Pabon, Emilia
AU - Ribiero, Carla M.
AU - Ricamara, Marivic
AU - Richter, Alex
AU - Ritchie, Neil
AU - Ritchie, Adam J.
AU - Robbins, Alexander J.
AU - Roberts, Hannah
AU - Robinson, Ryan E.
AU - Robinson, Hannah
AU - Rocchetti, Talita T.
AU - Rocha, Beatriz Pinho
AU - Roche, Sophie
AU - Rollier, Christine
AU - Rose, Louisa
AU - Ross Russell, Amy L.
AU - Rossouw, Lindie
AU - Royal, Simon
AU - Rudiansyah, Indra
AU - Ruiz, Sarah
AU - Saich, Stephen
AU - Sala, Claudia
AU - Sale, Jessica
AU - Salman, Ahmed M.
AU - Salvador, Natalia
AU - Salvador, Stephannie
AU - Sampaio, Milla
AU - Samson, Annette D.
AU - Sanchez-Gonzalez, Amada
AU - Sanders, Helen
AU - Sanders, Katherine
AU - Santos, Erika
AU - Santos Guerra, Mayara F.S.
AU - Satti, Iman
AU - Saunders, Jack E.
AU - Saunders, Caroline
AU - Sayed, Aakifah
AU - Schim van der Loeff, Ina
AU - Schmid, Annina B.
AU - Schofield, Ella
AU - Screaton, Gavin
AU - Seddiqi, Samiullah
AU - Segireddy, Rameswara R.
AU - Senger, Roberta
AU - Serrano, Sonia
AU - Shah, Rajiv
AU - Shaik, Imam
AU - Sharpe, Hannah E.
AU - Sharrocks, Katherine
AU - Shaw, Robert
AU - Shea, Adam
AU - Shepherd, Amy
AU - Shepherd, James G.
AU - Shiham, Farah
AU - Sidhom, Emad
AU - Silk, Sarah E.
AU - da Silva Moraes, Antonio Carlos
AU - Silva-Junior, Gilberto
AU - Silva-Reyes, Laura
AU - Silveira, Anderson D.
AU - Silveira, Mariana B.V.
AU - Sinha, Jaisi
AU - Skelly, Donal T.
AU - Smith, Daniel C.
AU - Smith, Nick
AU - Smith, Holly E.
AU - Smith, David J.
AU - Smith, Catherine C.
AU - Soares, Airanuédida
AU - Soares, Tiago
AU - Solórzano, Carla
AU - Sorio, Guilherme L.
AU - Sorley, Kim
AU - Sosa-Rodriguez, Tiffany
AU - Souza, Cinthia M.C.D.L.
AU - Souza, Bruno S.D.F.
AU - Souza, Alessandra R.
AU - Spencer, Alexandra J.
AU - Spina, Fernanda
AU - Spoors, Louise
AU - Stafford, Lizzie
AU - Stamford, Imogen
AU - Starinskij, Igor
AU - Stein, Ricardo
AU - Steven, Jill
AU - Stockdale, Lisa
AU - Stockwell, Lisa V.
AU - Strickland, Louise H.
AU - Stuart, Arabella C.
AU - Sturdy, Ann
AU - Sutton, Natalina
AU - Szigeti, Anna
AU - Tahiri-Alaoui, Abdessamad
AU - Tanner, Rachel
AU - Taoushanis, Carol
AU - Tarr, Alexander W.
AU - Taylor, Keja
AU - Taylor, Ursula
AU - Taylor, Iona Jennifer
AU - Taylor, Justin
AU - te Water Naude, Rebecca
AU - Themistocleous, Yrene
AU - Themistocleous, Andreas
AU - Thomas, Merin
AU - Thomas, Kelly
AU - Thomas, Tonia M.
AU - Thombrayil, Asha
AU - Thompson, Fawziyah
AU - Thompson, Amber
AU - Thompson, Kevin
AU - Thompson, Ameeka
AU - Thomson, Julia
AU - Thornton-Jones, Viv
AU - Tighe, Patrick J.
AU - Tinoco, Lygia Accioly
AU - Tiongson, Gerlynn
AU - Tladinyane, Bonolo
AU - Tomasicchio, Michele
AU - Tomic, Adriana
AU - Tonks, Susan
AU - Towner, James
AU - Tran, Nguyen
AU - Tree, Julia
AU - Trillana, Gerry
AU - Trinham, Charlotte
AU - Trivett, Rose
AU - Truby, Adam
AU - Tsheko, Betty Lebogang
AU - Turabi, Aadil
AU - Turner, Richard
AU - Turner, Cheryl
AU - Ulaszewska, Marta
AU - Underwood, Benjamin R.
AU - Varughese, Rachel
AU - Verbart, Dennis
AU - Verheul, Marije
AU - Vichos, Iason
AU - Vieira, Taiane
AU - Waddington, Claire S.
AU - Walker, Laura
AU - Wallis, Erica
AU - Wand, Matthew
AU - Warbick, Deborah
AU - Wardell, Theresa
AU - Warimwe, George
AU - Warren, Sarah C.
AU - Watkins, Bridget
AU - Watson, Ekaterina
AU - Webb, Stewart
AU - Webb-Bridges, Alice
AU - Webster, Angela
AU - Welch, Jessica
AU - Wells, Jeanette
AU - West, Alison
AU - White, Caroline
AU - White, Rachel
AU - Williams, Paul
AU - Williams, Rachel L.
AU - Winslow, Rebecca
AU - Woodyer, Mark
AU - Worth, Andrew T.
AU - Wright, Danny
AU - Wroblewska, Marzena
AU - Yao, Andy
AU - Zimmer, Rafael
AU - Zizi, Dalila
AU - Zuidewind, Peter
N1 - Funding Information: This Article was funded by UK Research and Innovation, NIHR, Coalition for Epidemic Preparedness Innovations, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D'Or, the Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca. The authors dedicate this paper to the many healthcare workers who have lost their lives during the pandemic. This report is independent research funded by the UK National Institute for Health Research, UK Research and Innovation, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D'OR, the Brava and Telles Foundation, and the South African Medical Research Council. We are grateful to the NIHR infrastructure provided through the NIHR Biomedical Research Centres and the NIHR Clinical Research Network at the UK study sites. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. PMF received funding from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (finance code 001). The authors are grateful to the volunteers who participated in this study. The authors are grateful to the senior management at AstraZeneca for facilitating and funding the manufacture of the AZD1222 vaccine candidate and for financial support for expansion of the Oxford sponsored clinical trials in Brazil. AstraZeneca reviewed the data from the study and the final manuscript prior to submission, but the authors retained editorial control. Funding Information: This Article was funded by UK Research and Innovation, NIHR, Coalition for Epidemic Preparedness Innovations, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D’Or, the Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca. The authors dedicate this paper to the many healthcare workers who have lost their lives during the pandemic. This report is independent research funded by the UK National Institute for Health Research, UK Research and Innovation, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D’OR, the Brava and Telles Foundation, and the South African Medical Research Council. We are grateful to the NIHR infrastructure provided through the NIHR Biomedical Research Centres and the NIHR Clinical Research Network at the UK study sites. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. PMF received funding from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (finance code 001). The authors are grateful to the volunteers who participated in this study. The authors are grateful to the senior management at AstraZeneca for facilitating and funding the manufacture of the AZD1222 vaccine candidate and for financial support for expansion of the Oxford sponsored clinical trials in Brazil. AstraZeneca reviewed the data from the study and the final manuscript prior to submission, but the authors retained editorial control. Publisher Copyright: © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2021/1/9
Y1 - 2021/1/9
N2 - Background: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. Funding: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.
AB - Background: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. Funding: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.
UR - http://www.scopus.com/inward/record.url?scp=85097463811&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(20)32661-1
DO - 10.1016/S0140-6736(20)32661-1
M3 - Article
C2 - 33306989
AN - SCOPUS:85097463811
SN - 0140-6736
VL - 397
SP - 99
EP - 111
JO - The Lancet
JF - The Lancet
IS - 10269
ER -